Believing that antibodies hold the greatest potential to successfully address the unmet clinical needs resulting from dysfunction of essential proteases and other enzymes, we are advancing a pipeline of highly specific and differentiated inhibitory antibody candidates to treat a broad array of inflammatory diseases.

By selecting upstream, potentially causal targets, we seek to inhibit the disease cascade and prevent the chronic inflammation, resultant barrier dysfunction, and generation of antigenic peptides that are hallmarks of these diseases.